Han Yu Pharmaceutical and KuCoin reach strategic cooperation to explore innovative drug RWA project.

According to the news from Han Yu Pharmaceuticals, on August 4th, Han Yu Pharmaceuticals officially signed a strategic cooperation memorandum with the digital asset platform KuCoin. Both parties intend to jointly explore the pilot project of tokenizing RWA with "future revenue rights of innovative drug research and development" as the underlying asset in Hong Kong, which is the first of its kind in mainland China. Under the agreement, Han Yu Pharmaceuticals will use its technical knowledge and research and development pipeline in the field of GLP-1 peptide heavyweight drugs as the underlying assets, while KuCoin will leverage its advantages in blockchain technology, RWA full-process solutions, and global compliance resources to provide integrated support such as on-chain mapping, asset tokenization, trading matching, and revenue distribution for the project.